 (1987) 
In nineteen patients with portal hypertension and oesophageal varices, transmural variceal blood pressure was determined endoscopically by direct puncture of the varices before and after intravenous administration of 20 mg metoclopramide or placebo. No change in pressure was observed after placebo (mean difference -1.3 _ _ . 24 .5%, N.S.), however, metociopramide reduced the pressure by 17 It therefore seems clear that the critical area of rupture of varices appears to be the lower 2cm to 5cm of the oesophagus and this may be related to the now well described anatomical features of the venous drainage of this area which teleologically may be related to the presence of the lower oesophageal sphincter mechanism1.
Fifteen years ago Cohen and his colleagues showed that metoclopramide gave a dose-related increase in the lower oesophageal pressure both in response to oral and intravenous administration of the drug12. However, it should be noted that the accepted oral dose at that time was 10mg and this gave only a slight increase in the lower oesophageal pressure which was not consistent in all of their patients.
Subsequently the Danish group in a very small series of patients (6) and using a rather crude technique of measuring blood flow showed that metoclopramide decreased the flow to the varices in five patients, and they related this to the increase in the lower oesophageal sphincter pressure produced by the drug13.
Subsequently Lunderquist, using percutaneous transhepatic portography in patients with portal hypertension and oesophageal varices showed that a number of drugs could decrease variceal blood flow through the lower oesophagus. Although the number of patients was very small the group showed that vasopressin did not change the variceal blood flow. However, pentagastrin, presumably with its effect of increasing the lower oesophageal sphincter pressure, interrupted the blood flow, through the varices, in four of eight patientsTM.
In studies using azygos blood flow measurements in a small group of six patients from Lebrec's group, while an increase in lower oesophageal sphincter pressure induced by domperidone was found, azygos blood was unaltered15. However, in a larger series of patients contrary data from the Barcelona group has been published. In 33 patients with azygos venous blood flow measurements the administration of both metoclopramide and domperidone caused a significant reduction in azygos blood flow, compared to a placebo group. The authors concluded that this was a local effect of the drugs in increasing the lower oesophageal sphincter pressure as all the other parameters of portal pressure, hepatic blood flow and cardiac output remained unaltered16.
Transmural oesophageal variceal pressure has been shown to be easily measured by direct puncture of oesophageal varices17. Subsequently, the Sheffield group showed that pharmacological constriction of the lower oesophageal sphincter did reduce intravariceal pressure from a mean of 23mm Hg to 4mm Hg and these data were significant. In a subsequent small trial in Egyptian patients who were actively bleeding from varices in the lower 2cm of the oesophagus there appeared to be benefit in giving metoclopramideTM.
The current paper from Munich shows that 20mg of intravenous metoclopramide significantly reduced intravariceal pressure, compared to a placebo. The two groups in the study were comparable but nonetheless of a total of 50 patients being entered into the study, 31 of these had to be excluded, mainly because of unsatisfactory pressure recordings. Some of these unsatisfactory recordings were due to the varices being small and therefore difficulty may have occurred in inserting the needle into the varix. This could alter the results as it has been well shown that the larger varices tend to bleed more than smaller ones19. Furthermore, the numbers in the study were relatively small with ten and nine in each group. In addition, there were two patients, one in each group, who appeared to sustain a remarkably large drop in pressure and again this could alter the results.
Nonetheless, the data from the paper under review and that of other data in the literature indicate that overall there is probably a reduction in intravariceal pressure by metoclopramide. However, although the data show a reduction in intravariceal pressure with metoclopramide whether or not this can be translated into clinical benefit is currently unclear.
A further study from the Barcelona group has shown no benefit with either domperidone or metoclopramide given intravenously in patients who have had bleeding from oesophageal varices. In a controlled study there is no difference in re-bleeding rate compared to a placebo group, although the criteria for diagnosing re-bleeding from the varices in this study could be criticised2.
In summary it seems likely that increasing the lower oesophageal sphincter pressure by drugs such as metoclopramide increases the in-flow resistance into the varices and may shift the collateral blood flow into the peri-oesophageal veins21.
There is therefore a sound anatomical and physiological basis for this hypothesis but further clinical controlled trials are required.
